LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Daratumumab Use Prior to Kidney Transplant and T Cell-Mediated Rejection: A Case Report.

Scalzo, Riley E / Sanoff, Scott L / Rege, Aparna S / Kwun, Jean / Knechtle, Stuart J / Barisoni, Laura / Byrns, Jennifer S

American journal of kidney diseases : the official journal of the National Kidney Foundation

2023  Volume 81, Issue 5, Page(s) 616–620

Abstract: There is growing interest in daratumumab in the solid organ transplant realm owing to the potential immunomodulatory effects on CD38-expressing cells, primarily plasma cells, as they have a key role in antibody production. In particular there is interest ...

Abstract There is growing interest in daratumumab in the solid organ transplant realm owing to the potential immunomodulatory effects on CD38-expressing cells, primarily plasma cells, as they have a key role in antibody production. In particular there is interest in use of daratumumab for desensitization and potential treatment for antibody-mediated rejection. However, ongoing investigation with daratumumab has shown potential immunologic concerns in vitro, with a significant increase in populations of CD4-positive cytotoxic T cells and CD8-positive helper T cells in both peripheral blood and bone marrow that could lead to acute T cell-mediated rejection in the solid organ transplant patient. To date, there are no published reports of an association with daratumumab use and T cell-mediated rejection in vivo. In this case report we present what is to our knowledge the first documented case of an early severe T cell-mediated rejection in a low-immunologic-risk living-donor kidney transplant recipient who received daratumumab for multiple myeloma maintenance prior to transplant.
MeSH term(s) Humans ; Kidney Transplantation ; ADP-ribosyl Cyclase 1 ; Antibodies, Monoclonal/therapeutic use ; Multiple Myeloma/therapy ; T-Lymphocytes
Chemical Substances daratumumab (4Z63YK6E0E) ; ADP-ribosyl Cyclase 1 (EC 3.2.2.6) ; Antibodies, Monoclonal
Language English
Publishing date 2023-01-06
Publishing country United States
Document type Case Reports ; Research Support, Non-U.S. Gov't
ZDB-ID 604539-x
ISSN 1523-6838 ; 0272-6386
ISSN (online) 1523-6838
ISSN 0272-6386
DOI 10.1053/j.ajkd.2022.11.010
Shelf mark
Zs.A 1669: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)
Zs.MO 468: Show issues
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top